Once-Weekly Insulin Added To Novo Nordisk’s Clinical Pipeline
This article was originally published in The Pink Sheet Daily
Novo Nordisk is evaluating new long-acting and quick-acting insulins in clinical trials as competitive pressure looks set to intensify in 2013 for its market-leading GLP-1 agonist, Victoza.
You may also be interested in...
Novo Nordisk and Allergan both report setbacks during their respective first quarter earnings calls. Meanwhile, Valeant and Actavis avoid speculation about a potential merger, and other Q1 happenings.
FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.
In this earnings round up, we zoom in on Merck and Novo Nordisk’s performance in emerging markets for 2012.